دورية أكاديمية
Fenofibrate's impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study.
| العنوان: | Fenofibrate's impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study. |
|---|---|
| المؤلفون: | Hong S; Department of Internal Medicine, Guri Hospital, College of Medicine, Hanyang University, Seoul, Republic of Korea., Kim KS; Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea., Han K; Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea., Park CY; Division of Endocrinology and Metabolism, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Pyung-Dong, Jongro-Gu, (03181), Seoul, Republic of Korea. cydoctor@chol.com. |
| المصدر: | Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Jul 18; Vol. 23 (1), pp. 263. Date of Electronic Publication: 2024 Jul 18. |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : BioMed Central, [2002- |
| مواضيع طبية MeSH: | Fenofibrate*/therapeutic use , Fenofibrate*/adverse effects , Hypolipidemic Agents*/therapeutic use , Hypolipidemic Agents*/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects , Propensity Score* , Heart Disease Risk Factors* , Databases, Factual* , Biomarkers*/blood, Humans ; Male ; Female ; Middle Aged ; Republic of Korea/epidemiology ; Aged ; Treatment Outcome ; Risk Assessment ; Time Factors ; Diabetes Mellitus/epidemiology ; Diabetes Mellitus/diagnosis ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus/mortality ; Diabetes Mellitus/blood ; Triglycerides/blood ; Myocardial Infarction/mortality ; Myocardial Infarction/epidemiology ; Myocardial Infarction/diagnosis ; Myocardial Infarction/blood ; Cause of Death ; Stroke/mortality ; Stroke/epidemiology ; Stroke/prevention & control ; Stroke/diagnosis ; Stroke/blood ; Retrospective Studies ; Protective Factors ; Cardiovascular Diseases/mortality ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/blood |
| مستخلص: | Background: The beneficial effects of fenofibrate on atherosclerotic cardiovascular disease (ASCVD) outcomes in patients with diabetes and statin treatment are unclear. We investigated the effects of fenofibrate on all-cause mortality and ASCVD in patients with diabetes, high triglyceride (TG) levels and statin treatment. Methods: We performed a nationwide propensity-score matched (1:1) cohort study using data from the National Health Information Database in the Republic of Korea from 2010 to 2017. The study included 110,723 individuals with diabetes, TG levels ≥ 150 mg/dL, and no prior diagnoses of ASCVD who used statins and fenofibrate, and an equal matched number of similar patients who used statins alone (control group). The study outcomes included newly diagnosed myocardial infarction (MI), stroke, both (MI and/or stroke), and all-cause mortality. Results: Over a mean 4.03-year follow-up period, the hazard ratios (HR) for outcomes in the fenofibrate group in comparison to the control group were 0.878 [95% confidence interval (CI) 0.827-0.933] for MI, 0.901 (95% CI 0.848-0.957) for stroke, 0.897 (95% CI 0.858-0.937) for MI and/or stroke, and 0.716 (95% CI 0.685-0.749) for all-cause death. These beneficial effects of fenofibrate were consistent in the subgroup with TG 150-199 mg/dL but differed according to low-density lipoprotein cholesterol (LDL-C) levels. Conclusion: In this nationwide propensity-score matched cohort study involving individuals with diabetes and TG ≥ 150 mg/dL, the risk of all-cause death and ASCVD was significantly lower with fenofibrate use in conjunction with statin treatment compared to statin treatment alone. However, this finding was significant only in individuals with relatively high LDL-C levels. (© 2024. The Author(s).) |
| References: | Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. (PMID: 10.1186/s12933-018-0728-6298841915994068) Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246. (PMID: 10.4239/wjd.v6.i13.1246264683414600176) Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 1998;316(7134):823–8. (PMID: 10.1136/bmj.316.7134.823954945228484) Yang YS, Kim HL, Kim SH, Moon MK. Lipid management in Korean people with type 2 diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and atherosclerosis Consensus Statement. Diabetes Metab J. 2023;47(1):1–9. (PMID: 10.4093/dmj.2022.0448367271609925153) ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, et al. 10. Cardiovascular Disease and Risk Management: standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S158–90. (PMID: 10.2337/dc23-S01036507632) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. (PMID: 10.1093/eurheartj/ehz45531504418) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 139(25):e1082-e1143. Blais JE, Ye X, Wan EYF, Wong WCW, Wong ICK, Tomlinson B, Chan EW. Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular events: a retrospective cohort study of 223,699 primary care patients. Clin Drug Investig. 2022;42(11):987–97. (PMID: 10.1007/s40261-022-01208-936239913) Ting RZ, Yang X, Yu LW, Luk AO, Kong AP, Tong PC, So WY, Chan JC, Ma RC. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol. 2010;9:77. (PMID: 10.1186/1475-2840-9-77210921823004819) Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. (PMID: 10.1056/NEJMoa1001282) Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, Fenofibrate I. Event lowering in diabetes study I: effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetes Care. 2009;32(3):493–8. (PMID: 10.2337/dc08-1543189847742646035) Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–84. (PMID: 10.1016/S0140-6736(10)60656-320462635) Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, et al. Triglyceride lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923–34. (PMID: 10.1056/NEJMoa221064536342113) Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort Profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017;46(2):e15. (PMID: 26822938) Song SO, Jung CH, Song YD, Park CY, Kwon HS, Cha BS, Park JY, Lee KU, Ko KS, Lee BW. Background and data configuration process of a nationwide population-based study using the Korean national health insurance system. Diabetes Metab J. 2014;38(5):395–403. (PMID: 10.4093/dmj.2014.38.5.395253498274209354) Lim SS, Lee W, Kim YK, Kim J, Park JH, Park BR, Yoon JH. The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011–2015. Orphanet J Rare Dis. 2019;14(1):49. (PMID: 10.1186/s13023-019-1032-6307771106379926) Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. (PMID: 10.1093/eurheartj/ehx144284442905837225) Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–30. (PMID: 10.1093/eurheartj/ehz962320528337308544) Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–806. (PMID: 10.1093/eurheartj/ehab551344725868670783) Castaner O, Pinto X, Subirana I, Amor AJ, Ros E, Hernaez A, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Estruch R, et al. Remnant cholesterol, not LDL cholesterol, is Associated With Incident Cardiovascular Disease. J Am Coll Cardiol. 2020;76(23):2712–24. (PMID: 10.1016/j.jacc.2020.10.00833272365) Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-Rich Lipoprotein Cholesterol, small dense LDL cholesterol, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2020;75(17):2122–35. (PMID: 10.1016/j.jacc.2020.02.059323543808064770) Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65(21):2267–75. (PMID: 10.1016/j.jacc.2015.03.54426022813) Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and risk of Cardiovascular events among patients receiving statin therapy in the TNT Trial. Circulation. 2018;138(8):770–81. (PMID: 10.1161/CIRCULATIONAHA.117.03231829618599) Genetics TCD, Emerging Risk Factors C, Sarwar C, Sandhu N, Ricketts MS, Butterworth SL, Di Angelantonio AS, Boekholdt E, Ouwehand SM, Watkins W. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634–9. (PMID: 10.1016/S0140-6736(10)60545-4) Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–52. (PMID: 10.1038/ng.2795240970643904346) Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, Dale CE, Padmanabhan S, Finan C, Swerdlow DI, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539–50. (PMID: 10.1093/eurheartj/eht57124474739) Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, et al. Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse Cardiovascular events in patients at High Cardiovascular Risk: the STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268–80. (PMID: 10.1001/jama.2020.22258331901477667577) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr., Juliano RA, Jiao L, Granowitz C, et al. Cardiovascular Risk reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. (PMID: 10.1056/NEJMoa181279230415628) Marston NA, Giugliano RP, Im K, Silverman MG, O’Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association between triglyceride lowering and reduction of Cardiovascular Risk Across multiple lipid-lowering therapeutic classes: a systematic review and Meta-regression analysis of Randomized controlled trials. Circulation. 2019;140(16):1308–17. (PMID: 10.1161/CIRCULATIONAHA.119.041998315300086791781) Nelson JR, Budoff MJ, Wani OR, Le V, Patel DK, Nelson A, Nemiroff RL. EPA’s pleiotropic mechanisms of action: a narrative review. Postgrad Med. 2021;133(6):651–64. (PMID: 10.1080/00325481.2021.192149133900135) Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. (PMID: 10.1056/NEJMoa1107579) Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61. (PMID: 10.1016/S0140-6736(05)67667-216310551) Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15(19):5336–48. (PMID: 10.1002/j.1460-2075.1996.tb00918.x8895578452277) Kim NH, Kim SG. Fibrates revisited: potential role in Cardiovascular Risk reduction. Diabetes Metab J. 2020;44(2):213–21. (PMID: 10.4093/dmj.2020.0001323470237188966) Feng X, Gao X, Jia Y, Zhang H, Pan Q, Yao Z, Yang N, Liu J, Xu Y, Wang G, Yang X. PPAR-alpha Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. PPAR Res 2015, 2015:924131. Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. Am J Cardiol. 2011;107(7):1010–e10181011. (PMID: 10.1016/j.amjcard.2010.11.02321276586) Kim KS, Hong S, Han K, Park CY. Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels. Metabolism. 2022;137:155327. (PMID: 10.1016/j.metabol.2022.15532736202222) Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019;366:l5125. (PMID: 10.1136/bmj.l5125315621176763755) |
| فهرسة مساهمة: | Keywords: Cardiovascular diseases; Diabetes; Fenofibrate; Mortality; Statin; Triglycerides |
| المشرفين على المادة: | U202363UOS (Fenofibrate) 0 (Hypolipidemic Agents) 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) 0 (Biomarkers) 0 (Triglycerides) |
| تواريخ الأحداث: | Date Created: 20240718 Date Completed: 20240719 Latest Revision: 20240719 |
| رمز التحديث: | 20240720 |
| DOI: | 10.1186/s12933-024-02353-5 |
| PMID: | 39026240 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1475-2840 |
|---|---|
| DOI: | 10.1186/s12933-024-02353-5 |